Market Highlights
The global fetal macrosomia market has been evaluated as a steady market and it is expected to continue growing in the near future. Increasing incidence of fetal macrosomia is the major driver for this market. Introduction and increasing adoption of advanced diagnostic tools for effective diagnostic and treatment management is another important factor for the market growth. Companies are investing in development of new and innovative device development is also key driver for the market growth.
The market for fetal macrosomia was around USD 2290.2 million in 2016 and is expected to reach USD 3034.1 million by 2023 which is a projected CAGR of 4.1%.
Major players in fetal macrosomia market
There are plenty of large and small market players which operate in this market: Carestream Health (US), Esaote SpA (Italy), Fonar Corporation (US), Fujifilm Holdings Corporation (Japan), GE Healthcare (UK), Hitachi Medical Corporation (Japan), Hologic, Inc. (US), Philips Healthcare (Netherlands), Samsung Medison Co. Ltd (Republic of Korea), Shimadzu Corporation (Japan), Siemens Healthcare (Germany), Toshiba Corporation (Japan),) and others.
Regional Analysis:
Considering the global scenario of the fetal macrosomia market, there are four main regions, America, Europe, Asia Pacific, and Middle East Africa.
America is the largest market for fetal macrosomia. The Americas mainly include North America and South America. North America is holding the largest market share in which US is dominating this market. Some major factors like advanced diagnostic and treatment facilities, rapid adoption of healthcare practices, and increasing investment in research are the driving forces for the growth for North America fetal macrosomia market. European region is the second important market, especially West European countries are dominating this region. Eastern European countries are also showing significant growth in this market. Asia Pacific market is witnessing rapid growth due to increasing awareness of the diseases, increasing spending and government initiative to increase awareness as well as to provide affordable healthcare. Talking about the market scenario of Middle East Africa, this region is expected to grow slower than the global average due to various inhibiting factors such as lack of knowledge, limited access to the required healthcare facilities, traditional healthcare facilities etc.
Segmentation:
Global fetal macrosomia market has been segmented on the basis of diagnosis which comprise of ultrasound, antenatal testing, and others. Ultrasound is further sub-segmented into standard ultrasound, transvaginal scan, fetal echocardiography, 3-d ultrasound, dynamic 3-d ultrasound, and others. Antenatal testing is further sub-segmented into blood and urine tests, amniocentesis, chorionic villus sampling, and others.
On the basis of treatments, the market has been segmented into medical care, surgical care, and others. Surgical Care is sub-segmented into cesarean delivery, and others.
On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.
